Anti-inflammatory mechanisms of the vascular smooth muscle PPARγ

Masashi Mukohda* and Hiroshi Ozaki

Laboratory of Veterinary Pharmacology, Faculty of Veterinary Medicine, Okayama University of Science, Imabari, Ehime 794-8555, Japan

Submitted September 14, 2020; accepted in final form January 22, 2021

Abstract

This review highlights molecular mechanisms of anti-inflammatory and protective effects of the nuclear transcription factor, peroxisome proliferator-activated receptor γ (PPARγ) in vascular tissue. PPARγ is an ubiquitously expressed nuclear factor, and well-studied in adipose tissue and inflammatory cells. Additionally, beneficial effects of vascular PPARγ’s on atherosclerosis and vascular remodeling/dysfunction have been reported although the detailed mechanism remains to be completely elucidated. Clinical and basic studies have shown that the synthetic PPARγ ligands, thiazolidinediones (TZDs), have protective effects against cardiovascular diseases such as atherosclerosis. Recent studies utilizing genetic tools suggested that those protective effects of TZDs on cardiovascular diseases are not due to a consequence of improvement of insulin resistance, but may be due to a direct effect on PPARγ’s in vascular endothelial and smooth muscle cells. In this review, we discuss proposed mechanisms by which the vascular PPARγ regulates vascular inflammation and remodeling/dysfunction especially in smooth muscle cells.

Key words: PPARγ, vascular dysfunction, smooth muscle, inflammation

Introduction

The PPARγ is an ubiquitously expressed and well-studied nuclear factor in the field of metabolism (1) and immunity (2, 3). For example, PPARγ controls adipogenesis, lipid metabolisms and glucose homeostasis by regulating numerous genes including aP2, C/EBPα, FGF21, and Glut4. PPARγ activation promotes glucose uptake as well as lipid storage (4, 5), and decreases gluconeogenesis (6) resulting in an enhancement of insulin sensitivity (7). Therefore, synthetic PPARγ agonists, thiazolidinediones (TZDs), are used as medication for type 2 diabetes. Although the mechanisms of PPARγ action remain less known in other tissues than adipose tissue, synthesized PPARγ agonists such as pioglitazone have impressive cardiovascular benefits such
as decreased risk of heart disease, stroke, and atherosclerosis (7–9). It is reported that the protective effect on cardiovascular disease, especially atherosclerosis, was due to a direct effect of PPARγ activation on atheroma and vascular walls, but not a consequence of improvement of insulin resistance (10). Consistently, studies using genetically engineered animal models have shown that PPARγ’s, in both vascular endothelium and smooth muscle, plays a crucial role in regulating vascular homeostasis independently of systemic metabolisms. Here, we will review the advances in the studies of protective mechanisms of vascular PPARγ, especially focusing on vascular smooth muscle cells (SMC).

**Vascular-PPARγ’s and Atherosclerosis**

Large clinical studies indicated that TZDs have protective effects on vascular events including coronary disease, atherosclerosis, and stroke in patients with Type 2 diabetes (8, 11, 12). One of the studies has shown that treatment of prediabetes with pioglitazone decreased progression of carotid intima media thickness independently of the effects on blood glucose and lipid, insulin resistance, or blood inflammatory markers (13). Thus, the protection was suggested to be associated with PPARγ activation in immune cells and/or vascular cells such as endothelial cells (ECs) and SMC’s. Indeed, there are several reports showing that vascular PPARγ’s exert protective roles by regulating initiation and development of atherogenesis. LDL receptor knockout mice with EC-PPARγ deletion showed accelerated initiation of atherosclerotic lesion formation compared to controls or LDLR knockout mice with macrophage-PPARγ deletion when fed with a high-cholesterol diet (14). In transplantation of carotid artery to CBA/CaJ recipient mice, exaggerated development of the lesion formation with increased inflammatory cell infiltration and TNF-α expression was observed in the carotid arteries from SMC-PPARγ deletion mice (15). After 2 weeks of the transplantation, NF-κB activity and VCAM-1 expression in the lesion were strongly elevated in SMC-PPARγ KO mice. Atherosclerotic lesion was also exacerbated in apolipoprotein E (ApoE)-deficient mice crossed with SMC-PPARγ KO mice compared to littermate control fed with a high cholesterol diet (16). Interestingly, this report demonstrated that ApoE- and SMC-PPARγ-deficient mice showed loss of perivascular adipose tissues, resulting in loss of the protective effect on development of atherosclerosis.

P467L- or V290M-mutation of the PPARγ is known to be a loss-of-function mutation causing insulin resistance and blood pressure elevation in human subjects. Mice expressing dominant-negative (DN) mutant PPARγ (P467L or V290M) crossed with ApoE-deficient mice showed increased atheroma formation when fed with a high cholesterol diet (17). In the aortic lesions, expression of NF-κB target genes such as VCAM-1 and MCP1 was increased in EC- or SMC-DN PPARγ mutant mice compared to littermate control. Because proliferation and migration of vascular SMC, which are deeply associated with NF-κB activation, are one of the steps for development of atherosclerosis, PPARγ-NF-κB interaction might be essential for TZD-induced anti-atherosclerotic effects.

**PPARγ and NF-κB**

Ligand dependent PPARγ activation regulates numerous genes with a heterodimeric partner, retinoid X receptor (RXR) when bound to specific regions on the DNA of target genes termed PPAR response element (PPRE). The PPARγ also functions in protein-protein interaction, and one of the crucial target proteins is NF-κB. PPARγ-NF-κB interaction has been reported in various cell types (Fig. 1). In macrophage, PPARγ’s inhibited NF-κB activity and its downstream pro-inflammatory pathway via transrepression mechanisms in
Role of PPARγ in vascular inflammation

In the nucleus, PPARγ inhibits NF-κB activity and its downstream pro-inflammatory pathway via transrepression mechanisms in a way that PPARγ directly binds to the corepressor complex on the promoters of NF-κB target genes. PPARγ also binds to NF-κB subunit, p65 which exports it to cytoplasm, resulting in inhibition of NF-κB activity. In addition, PPARγ acts as an E3 ubiquitin ligase and induces degradation of p65, which inhibits NF-κB-mediated inflammation.

**Fig. 1.** Schematic view of possible PPARγ-NF-κB interaction in vascular SMC. In the nucleus, PPARγ inhibits NF-κB activity and its downstream pro-inflammatory pathway via transrepression mechanisms in a way that PPARγ directly binds to the corepressor complex on the promoters of NF-κB target genes. PPARγ also binds to NF-κB subunit, p65 which exports it to cytoplasm, resulting in inhibition of NF-κB activity. In addition, PPARγ acts as an E3 ubiquitin ligase and induces degradation of p65, which inhibits NF-κB-mediated inflammation.

Animal studies revealed that agonist-mediated activation of PPARγ’s could reverse pulmonary arterial hypertension with improved plasma levels of adiponectin and insulin sensitivity (23). In contrast, SMC-PPARγ deletion mice spontaneously developed pulmonary arterial hypertension, which is characterized as pulmonary arterial remodeling, and elevated right ventricle systolic pressure and hypertrophy (24). The authors also demonstrated that inhibition of PPARγ’s in pulmonary arterial SMCs caused activation of TGFβ1 signaling.
both in vivo and in vitro (25). In this context, SMC-PPARγ directly binds to Smad3/Stat3, and inhibits TGFβ1-induced glucose metabolism and pulmonary arterial hypertension. In addition, LDL receptor-related protein 1 (LRP1) in vascular SMC, which was decreased in human pulmonary hypertension, protected pulmonary arterial remodeling and PPARγ activation by pioglitazone reversed pulmonary hypertension caused by LRP1 deficiency in SMC (26). The protective mechanism of SMC-PPARγ was due to inhibition of Smad3, Nox4 and CTGF, TGFβ1 downstream target. Another group has revealed that loss-of-function of PPARγ’s in SMC caused systemic hypertension (27). Mice expressing the DN PPARγ mutation (P467L) in vascular SMC showed systolic hypertension and vascular dysfunction via increased Rho kinase (28) and decreased NO sensitivity (29). The PPARγ target gene, RhoBTB1, which acts as an adaptor of the Cullin-3 E3 ring ubiquitin ligase complex (CRL3), was significantly decreased in mutant mice (30). The authors further demonstrated that the mechanisms linking the mutation in SMC-PPARγ and hypertension is critically involved in Cullin-3. In SMC, RhoA and phosphodiesterase 5 are substrates for CRL3 (29, 31) and either the loss-of-function mutation or the deletion of Cullin-3 in SMC caused severe hypertension and vascular dysfunction with increased RhoA kinase and decreased nitric oxide (NO) sensitivity (32, 33). Another study revealed that mice expressing DN PPARγ in SMC exhibited augmented hypertension and vascular remodeling caused by deoxycorticosterone acetate-salt (34). They identified tissue inhibitor of metalloproteinase-4 (TIMP-4) as a new PPARγ target gene in SMC and found TIMP-4 tightly regulated SMC migration and vascular remodeling, which consequently influenced the regulation of systemic blood pressure. These data indicate that SMC-PPARγ plays a crucial role in vascular homeostasis and blood pressure regulation with manipulating several key genes and pathways.

### Conclusion and Future Study

The PPARγ has been reported to have plentiful beneficial effects on not only adipose tissue, liver, and immune cell, but also on vascular tissues. On the other hand, TZDs are well-known to have several side effects such as weight gain, fluid retention and edema, bone fractures, and bladder cancer (10, 35–39). Therefore, new drugs without off-target effects or with tissue-selective activation of PPARγ are warranted. Similarly, identifying a new target associated with PPARγ will help us to design a new class of therapies that regulate PPARγ function more selectively.

### Conflicts of Interest

None.

### Acknowledgment

We sincerely would like to thank Dr. Shuichi Tawara at Okayama University of Science for important suggestions.

### References

1. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013; 19(5): 557–66. [Medline] [CrossRef]

2. Szanto A, Balint BL, Nagy ZS, Barta E, Dezso B, Pap A, Szeles L, Poliska S, Oros M, Evans RM, Barak Y, Schwabe J, Nagy L. STAT6 transcription factor is a facilitator of the nuclear receptor PPARγ-
regulated gene expression in macrophages and dendritic cells. Immunity. 2010; 33(5): 699–712. [Medline] [CrossRef]

3. Széles L, Töröcsik D, Nagy L. PPARgamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta. 2007; 1771(8): 1014–30. [Medline] [CrossRef]

4. Kim JK, Fillmore JJ, Gavrilova O, Chao L, Higashimori T, Choi H, Kim HJ, Yu C, Chen Y, Qu X, Haluzik M, Reitman ML, Shulman GI. Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes. 2003; 52(6): 1311–8. [Medline] [CrossRef]

5. Ye JM, Dzamko N, Cleasby ME, Hegarty BD, Furler SM, Cooney GJ, Kraegen EW. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia. 2004; 47(7): 1306–13. [Medline] [CrossRef]

6. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem. 2003; 278(36): 34268–76. [Medline] [CrossRef]

7. Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014; 20(4): 573–91. [Medline] [CrossRef]

8. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Defèvre PJ, Murray GD, Taton J, PROactive Investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493): 1279–89. [Medline] [CrossRef]

9. Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL, BARI 2D Investigators Rosiglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006; 296(21): 2572–81. [Medline] [CrossRef]

10. Stump M, Mukohda M, Hu C, Sigmund CD. PPARγ regulation in hypertension and metabolic syndrome. Curr Hypertens Rep. 2015; 17(12): 89. [Medline] [CrossRef]

11. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Konodos GT, D’Agostino RB Sr, Perez A, Provost JC, Haffner SM. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006; 296(21): 2572–81. [Medline] [CrossRef]

12. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tzucu EM, PERISCOPE Investigators Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008; 299(13): 1561–73. [Medline] [CrossRef]

13. Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, Bray GA, Clement SC, Henry RR, Kitabchi AE, Mudadal S, Ratner RE, Stentz FB, Musi N, Tripathy D, DeFronzo RA, Reaven PD. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013; 33(2): 393–9. [Medline] [CrossRef]

14. Qu A, Shah YM, Manna SK, Gonzalez FJ. Disruption of endothelial peroxisome proliferator-activated receptor γ accelerates diet-induced atherogenesis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol. 2012; 32(1): 65–73. [Medline] [CrossRef]

15. Hamblin M, Chang L, Zhang H, Yang K, Zhang J, Chen YE. Vascular smooth muscle cell peroxisome proliferator-activated receptor-γ mediates pioglitazone-reduced vascular lesion formation. Arterioscler Thromb Vasc Biol. 2011; 31(2): 352–9. [Medline] [CrossRef]

16. Chang L, Villacorta L, Li R, Hamblin M, Xu W, Dou C, Zhang J, Wu J, Zeng R, Chen YE. Loss of
In perivascular adipose tissue on peroxisome proliferator-activated receptor-γ deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis. Circulation. 2012; 126(9): 1067–78. [Medline] [CrossRef]

17. Pelham CJ, Keen HL, Lentz SR, Sigmund CD. Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle. Am J Physiol Regul Integr Comp Physiol. 2013; 304(9): R690–701. [Medline] [CrossRef]

18. Pascual G, Fong AL, Ogawa S, Gamiel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature. 2005; 437(7059): 759–63. [Medline] [CrossRef]

19. Kelly D, Campbell JJ, King TP, Grant G, Jansson EA, Coutts AG, Pettersson S, Conway S. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol. 2004; 5(1): 104–12. [Medline] [CrossRef]

20. Hou Y, Moreau F, Chadee K. PPARγ is an E3 ligase that induces the degradation of NFκB/p65. Nat Commun. 2012; 3: 1300. [Medline] [CrossRef]

21. Mukohda M, Lu KT, Guo DF, Wu J, Keen HL, Liu X, Ketsawatsomkron P, Stump M, Rahmouni K, Quelle FW, Sigmund CD. Hypertension-causing mutation in peroxisome proliferator-activated receptor γ impairs nuclear export of nuclear factor-κB p65 in vascular smooth muscle. Hypertension. 2017; 70(1): 174–82. [Medline] [CrossRef]

22. Huang CD, Hsiung TC, Ho SC, Lee KY, Chan YF, Kuo LW, Lin SM, Wang CH, Lin HC, Kuo HP. PPARγ ligand ciglitazone inhibits TNFα-induced ICAM-1 in human airway smooth muscle cells. Biomed J. 2014; 37(4): 191–8. [Medline] [CrossRef]

23. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ, Rabinovitch M. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation. 2007; 115(10): 1275–84. [Medline] [CrossRef]

24. Hansmann G, de Jesus Perez VA, Alastalo TP, Alvira CM, Guignabert C, Bekker JM, Schellong S, Urashima T, Wang L, Morrell NW, Rabinovitch M. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest. 2008; 118(5): 1846–57. [Medline] [CrossRef]

25. Calvier L, Chouvarine P, Legchenko E, Hoffmann N, Geldner J, Borchert P, Jonigk D, Mozes MM, Hansmann G. PPARγ links BMP2 and TGFβ1 pathways in vascular smooth muscle cells, regulating cell proliferation and glucose metabolism. Cell Metab. 2017; 25(5): 1118–1134.e7. [Medline] [CrossRef]

26. Calvier L, Boucher P, Herz J, Hansmann G. LR1 deficiency in vascular SMCs leads to pulmonary arterial hypertension that is reversed by PPARγ activation. Circ Res. 2019; 124(12): 1778–85. [Medline] [CrossRef]

27. Halabi CM, Beyer AM, de Lange WJ, Keen HL, Baumbach GL, Faraci FM, Sigmund CD. Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab. 2008; 7(3): 215–26. [Medline] [CrossRef]

28. Pelham CJ, Ketsawatsomkron P, Groh S, Grobe JL, de Lange WJ, Ibeawuchi SR, Keen HL, Weatherford ET, Faraci FM, Sigmund CD. Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARγ and RhoA/Rho-kinase. Cell Metab. 2012; 16(4): 462–72. [Medline] [CrossRef]

29. Mukohda M, Fang S, Wu J, Agbor LN, Nair AR, Ibeawuchi SC, Hu C, Liu X, Lu KT, Guo DF, Davis DR, Keen HL, Quelle FW, Sigmund CD. RhoBTB1 protects against hypertension and arterial stiffness by restraining phosphodiesterase 5 activity. J Clin Invest. 2019; 129(6): 2318–32. [Medline] [CrossRef]

30. Fang S, Sigmund CD. PPARγ and RhoBTB1 in hypertension. Curr Opin Nephrol Hypertens. 2020; 29(2): 161–70. [Medline] [CrossRef]

31. Ibeawuchi SR, Agbor LN, Quelle FW, Sigmund CD. Hypertension-causing mutations in cullin3 protein impair RhoA protein ubiquitination and augment the association with substrate adaptors. J Biol Chem.
Role of PPARγ in vascular inflammation

2015; 290(31): 19208–17. [Medline] [CrossRef]

32. Agbor LN, Ibeawuchi SC, Hu C, Wu J, Davis DR, Keen HL, Quelle FW, Sigmund CD. Cullin-3 mutation causes arterial stiffness and hypertension through a vascular smooth muscle mechanism. JCI Insight. 2016; 1(19): e91015. [Medline] [CrossRef]

33. Agbor LN, Nair AR, Wu J, Lu KT, Davis DR, Keen HL, Quelle FW, McCormick JA, Singer JD, Sigmund CD. Conditional deletion of smooth muscle Cullin-3 causes severe progressive hypertension. JCI Insight. 2019; 5: 129793. [Medline] [CrossRef]

34. Ketsawatsomkron P, Keen HL, Davis DR, Lu KT, Stump M, De Silva TM, Hilzendeger AM, Grobe JL, Faraci FM, Sigmund CD. Protective role for tissue inhibitor of metalloproteinase-4, a novel peroxisome proliferator-activated receptor-γ target gene, in smooth muscle in deoxycorticosterone acetate-salt hypertension. Hypertension. 2016; 67(1): 214–22. [Medline] [CrossRef]

35. Ryan KK, Li B, Grayson BE, Matter EK, Woods SC, Seeley RJ. A role for central nervous system PPAR-γ in the regulation of energy balance. Nat Med. 2011; 17(5): 623–6. [Medline] [CrossRef]

36. Lu M, Sarruf DA, Talukdar S, Sharma S, Li P, Bandyopadhyay G, Nalbandian S, Fan W, Gayen JR, Mahata SK, Webster NJ, Schwartz MW, Olefsky JM. Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med. 2011; 17(5): 618–22. [Medline] [CrossRef]

37. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004; 27(1): 256–63. [Medline] [CrossRef]

38. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA. 2009; 302(14): 1573–9. [Medline] [CrossRef]

39. Faillie JL, Petit P, Montastrap JL, Hillaire-Buys D. Scientific evidence and controversies about pioglitazone and bladder cancer: which lessons can be drawn? Drug Saf. 2013; 36(9): 693–707. [Medline] [CrossRef]